Disease Activity

Can biomarkers differentiate psoriatic arthritis from osteoarthritis?
Jian Tian, Chao Cheng, Fangjie Zhang

Annals of the Rheumatic Diseases Sep 2020, 79 (9) e112; DOI: 10.1136/annrheumdis-2019-215745
Response to: ‘Can biomarkers differentiate psoriatic arthritis from osteoarthritis?’ by Tian et al
Vinod Chandran, Richard J Cook, Dafna D Gladman

Annals of the Rheumatic Diseases Sep 2020, 79 (9) e113; DOI: 10.1136/annrheumdis-2019-215762
Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al
Antonis Fanouriakis, George K Bertsias, Dimitrios T Boumpas

Annals of the Rheumatic Diseases Sep 2020, 79 (9) e115; DOI: 10.1136/annrheumdis-2019-215746
SLE-DAS: ready for routine use?
Anoop Mathew, Kavadichanda G Chengappa, Sanket Shah, Vir Singh Negi

Annals of the Rheumatic Diseases Sep 2020, 79 (9) e116; DOI: 10.1136/annrheumdis-2019-215704
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Paul Emery, Gerd R Burmester, Esperanza Naredo, Luigi Sinigaglia, Ivan Lagunes, Franziska Koenigsbauer, Philip G Conaghan

Annals of the Rheumatic Diseases Aug 2020, 79 (8) 1023-1030; DOI: 10.1136/annrheumdis-2020-217246
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Joerg Christoph Henes, Joern Kekow, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Eva Seipelt, Christof Specker, Eugen Feist

Annals of the Rheumatic Diseases Aug 2020, 79 (8) 1090-1097; DOI: 10.1136/annrheumdis-2020-217155
Response to: ‘Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al’ by Vandergheynst et al
Rachel B Jones, Thomas F Hiemstra, Michael Walsh, David Jayne, Lorraine Harper

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e101; DOI: 10.1136/annrheumdis-2019-215658
Response to ‘Decision making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?’ by Deng et al
Luis Eduardo Coelho Andrade, Jan Damoiseaux, Edward K Chan

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e93; DOI: 10.1136/annrheumdis-2019-215640
Differentiating disease activity from damage in systemic sclerosis: it’s still early days!
Siddharth Jain, Shefali Khanna Sharma

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e98; DOI: 10.1136/annrheumdis-2019-215588
Response to: ‘Differentiating disease activity from damage in systemic sclerosis: it’s still early days!’ by Jain and Sharma
Mandana Nikpour

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e99; DOI: 10.1136/annrheumdis-2019-215639

Main menu

Disease Activity

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Disease Activity

Pages